The company has identified a development plan through in-depth literature analyses focused on Alzheimer’s disease, the CaSR transmembrane receptor, and the possible molecules known to modulate the CaSR receptor response

The company’s goal is therefore aimed at developing a technological platform aimed at developing treatments for leukemias and solid tumors.

Lighthouse Biotech is a project aimed at extracting circulating tumor cells from a simple blood draw, keeping them intact to avoid alteration of their metabolism, making them traceable even in very early stages of the disease

The start-up develops a liquid artificial retina to restore partial vision in degenerative retinal diseases.

The project focuses on the use of polymeric retinal prostheses and aims to treat retinal degeneration.

Utopia SIS and Pariter Partners invest in Lighthouse Biotech. Lighthouse Biotech aims to define new boundaries for oncology research through new liquid biopsy technologies

Drug Discovery & Clinic S.r.l. (DDC), a spin-off of the University of Turin dedicated to the development of a platform for the creation of potentially effective drugs for different oncological scenarios, namely leukemia and breast cancer.

Antonio Cabras has held institutional positions at national level in various legislatures, President of the Fondazione di Sardegna for about a decade

He currently serves as the General Manager since 2009, and Vice President since 2020, of Fondazione Golinelli.

Antonio Falcone boasts 25 years of experience in the Asset Management sector, having worked in prominent companies such as Gruppo Deutsche Bank, Diners Italia, Axa Assicurazioni, and Unicredit; with a significant track record of roles, functions, positions held, and objectives achieved.

Marina Golinelli, a board member of Utopia SIS since March 2021, is a shareholder and member of the Board of Directors of Alfasigma, one of the leading pharmaceutical companies with Italian capital, with an international presence in over 100 countries.

Utopia was established with the aim of bridging this gap through investments in high-potential start-ups operating in the Life Sciences sector.The startups of the future are those that pursue collective well-being throughout the value chain.

n 2013, he became a partner and CEO of Principia SGR, revitalizing its activity and creating the largest Italian VC Fund focused on Healthcare with over 200 million in assets.

Fondazione Golinelli was established in Bologna in 1988 by the entrepreneur and philanthropist Marino Golinelli.

Fondazione Sardegna supports public interest and social utility through art, culture, research, health, volunteering, and local development.

UTOPIA aims to carry out Seed and Series A operations in the Life Sciences sector, an industry with significant investment opportunities. In Italy, it is still relatively underrepresented and characterized by a gap in terms of VC investments compared to the leading countries of the European Union.